May 02, 2025

Personalizing Eating Disorder Care Advances, Study

A global research team reviewed current treatments for eating disorders and found that while personalization is seen as essential by patients and clinicians, most approaches still lack strong supporting evidence.

Conexiant

May 01, 2025

Phthalates Linked to Cardiovascular Mortality Globally

Researchers linked di-2-ethylhexylphthalate plastic exposure to over 350,000 cardiovascular deaths and 10 million years of life lost, supporting calls for international regulatory measures.

Conexiant

May 01, 2025

Medical Oddities: Brains Go on Pause

This week, some deepfakes have a pulse, bacteria booby-trap DNA, and your brain sometimes hits pause.

Conexiant

May 01, 2025

Stem Cell Therapies for Retinal Degenerations

Stem cell therapy harnesses the high regenerative potency of undifferentiated stem cells to replace diseased or dead cells. In recent years, stem cell therapy for retinal diseases has transitioned from preclinical investigation to early phase clinical trials with promising results. Both RPE replacement and photoreceptor transplantation strategies have shown the potential to preserve or restore visual function in conditions like AMD and RP, offering hope for conditions once considered irreversible.

Retinal Physician

May 01, 2025

Semaglutide Shows Potential in Liver Disease Trial

Phase 3 trial finds weekly semaglutide 2.4mg significantly improved liver histology in patients with MASH and moderate to advanced fibrosis.

Conexiant

April 30, 2025

ApoB Count and Lp(a) Levels Key to CAD Risk

Total apoB particle count and Lp(a) levels best reflect coronary artery disease risk, with researchers noting that lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P.

Conexiant

April 30, 2025

Is That IPA PFAS-Free?

“Approximately 18% of U.S. breweries are located within zip codes with detectable Per- and polyfluoroalkyl substances (PFAS) in drinking water."

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

Can Five Proteins Predict Liver Disease?

"Imagine if we could predict risk of metabolic dysfunction-associated steatotic liver disease (MASLD) years before it starts."

Conexiant